Download Full Text (717 KB)
Background: Intravenous immune globulin (IVIG) is a plasma-derived product from pooled donors. It has six FDA approved indications. It is also considered standard of care for a few other conditions in specific populations. Additionally, there is growing non-evidence-based use. Due to a global shortage, IVIG has become increasing difficult to obtain.
. . . .
Conclusions: Development, implementation, and promotion of adherence to an evidence-based criterion allowed our scarce IVIG supply to be sustained. Further refinement of the criteria for use is ongoing, as is an evaluation of IVIG utilization by indication, pre- and post-implementation. This process can be applied to other situations of scarce resources
Immunoglobulins, Intravenous; Evidence-Based Practice; Resource Allocation; Quality Improvement
Health and Medical Administration | Pharmacy and Pharmaceutical Sciences
National Healthcare Quality Week
Ogden, Richard K. Jr.; Millspaugh, Daniel L.; and O'Neal, Brian, "Development and Implementation of an Evidence-Based Process for Scarce Resource Allocation" (2019). Posters. 138.